可选产品分析
经您允许,我们会使用注重隐私的有限分析来了解哪些研究流程有效。我们不会使用广告跟踪器或会话录制。您可以在偏好设置中更改此选择。请阅读 隐私政策.
Veralto Corporation's published Reduce conclusion compares the analysis-date price with fair value and potential value. Read the full report for assumptions, evidence, and material risks.
| Market cap | $23.3B | |
|---|---|---|
| Revenue (ttm) | 5.7B | |
| Net income (ttm) | 988M | |
| EPS (ttm) | $3.97 | |
| Shares out | 243.8M | |
| P/E (trailing) | 25.9x | |
| P/E (forward) | 20.0x | |
| Dividend | $0.52 (0.51%) | |
| Volume | 2,001,839 | |
| Beta | 0.77 |
Recent price action with selectable time range.
| Item | P1 | P2 | P3 | P4 | P5 | Trend |
|---|---|---|---|---|---|---|
| Period | 2021-12-31 | 2022-12-31 | 2023-12-31 | 2024-12-31 | 2025-12-31 | Trend |
| Revenue | $4.70B | $4.87B | $5.02B | $5.19B | $5.50B | +4.0% |
| Gross profit | $2.71B | $2.76B | $2.90B | $3.11B | $3.30B | +5.0% |
| Operating income | $1.04B | $1.11B | $1.14B | $1.21B | $1.28B | +5.2% |
| Net income | $861.0M | $845.0M | $839.0M | $833.0M | $940.0M | +2.2% |
| EPS (diluted) | $3.50 | $3.43 | $3.40 | $3.34 | $3.76 | +1.8% |
| EBITDA | $1.15B | $1.20B | $1.21B | $1.28B | $1.35B | +4.1% |
| R&D | $244.0M | $217.0M | $225.0M | $253.0M | $266.0M | +2.2% |
| SG&A | $1.43B | $1.43B | $1.54B | $1.64B | $1.76B | +5.3% |
Recent company headlines from major financial publishers.
The Base scenario establishes Fair value at $79.82, implying a return of -16.4% at a probability of 60.0%. In this modal path, Veralto executes its compounder playbook with mid-single-digit revenue growth driven by the mission-critical replacement of testing consumables, proprietary reagents, and marking inks. Operating margins expand moderately as standalone public company overhead rationalizes and pricing power outpaces input inflation. The business generates exceptional free cash flow conversion on minimal capital expenditure requirements. However, because $95.44 already trades at an elevated forward earnings multiple above peer medians, total returns are restrained by multiple compression toward historical norms. Disconfirmation would occur if organic growth slips below nominal economic growth or if operating margins fail to improve over the FY2026 to FY2027 forecast period.
Under the Bull scenario, with Potential value of $94.43 representing a return of -1.1% at a probability of 20.0%, statutory water quality mandates accelerate globally. Tightening environmental standards for PFAS and micro-pollutants drive double-digit growth in analytical instrumentation and recurring consumable reagents across municipal utilities. Meanwhile, industrial water reuse investments surge and Product and Quality Innovation benefits from stringent pharmaceutical and packaging traceability regulations. Operating leverage through the Veralto Business System expands operating margins beyond historical highs, and disciplined bolt-on acquisitions in water analytics software accelerate earnings growth. This scenario would be disconfirmed if municipal infrastructure disbursements stall or if operating margin expansion plateaus before the conclusion of FY2027.
| Ke ↓ / g → | 2.5% | 2.8% | 3.0% | 3.3% | 3.5% |
|---|---|---|---|---|---|
| 6.9% | $87.8 | $90.8 | $94.1 | $97.9 | $102 |
| 7.4% | $81.2 | $83.6 | $86.2 | $89.2 | $92.4 |
| 7.9% | $75.8 | $77.7 | $79.8 | $82.2 | $84.7 |
| 8.4% | $71.2 | $72.8 | $74.5 | $76.4 | $78.5 |
| 8.9% | $67.2 | $68.6 | $70.0 | $71.6 | $73.3 |
Upcoming earnings date and setup when available.
每月发布的研究版本所给出的评级。评级比较分析日的价格与公允价值,并不记录判断是否正确。
| 年份 | 1月 | 2月 | 3月 | 4月 | 5月 | 6月 | 7月 | 8月 | 9月 | 10月 | 11月 | 12月 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026 |